ES2040232T3 - Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina. - Google Patents

Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.

Info

Publication number
ES2040232T3
ES2040232T3 ES198787115516T ES87115516T ES2040232T3 ES 2040232 T3 ES2040232 T3 ES 2040232T3 ES 198787115516 T ES198787115516 T ES 198787115516T ES 87115516 T ES87115516 T ES 87115516T ES 2040232 T3 ES2040232 T3 ES 2040232T3
Authority
ES
Spain
Prior art keywords
dihidropiridina
oral administration
medicinal preparations
single dose
administration containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787115516T
Other languages
English (en)
Inventor
Wolfgang Lahr
Hans Dr. Dipl.-Chem. Kohne
Frank Musculus
Hein-Uwe Dr. Schmersahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Rentschler Arzneimittel GmbH and Co KG
Original Assignee
Dr Rentschler Arzneimittel GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Rentschler Arzneimittel GmbH and Co KG filed Critical Dr Rentschler Arzneimittel GmbH and Co KG
Application granted granted Critical
Publication of ES2040232T3 publication Critical patent/ES2040232T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVAS PREPARACIONES SOLIDAS DE MEDICAMENTOS PARA ADMINISTRACION ORAL, QUE CONTIENEN DIHIDROPIRIDINA EN DOSIFICACIONES DE 10 A 240 MG Y QUE RESULTAN ADECUADAS PARA SU ADMINISTRACION COMO DOSIS DIARIA UNICA PARA EL TRATAMIENTO DE ENFERMEDADES DEL APARATO CIRCULATORIO Y DE LA HIPERTENSION.
ES198787115516T 1986-10-23 1987-10-22 Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina. Expired - Lifetime ES2040232T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863636123 DE3636123A1 (de) 1986-10-23 1986-10-23 Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten

Publications (1)

Publication Number Publication Date
ES2040232T3 true ES2040232T3 (es) 1993-10-16

Family

ID=6312339

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787115516T Expired - Lifetime ES2040232T3 (es) 1986-10-23 1987-10-22 Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.

Country Status (6)

Country Link
US (1) US5071642A (es)
EP (1) EP0265848B1 (es)
JP (1) JPH0737384B2 (es)
AT (1) ATE67677T1 (es)
DE (2) DE3636123A1 (es)
ES (1) ES2040232T3 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
CA2056032A1 (en) * 1990-11-29 1992-05-30 Minoru Aoki Hard capsule preparation
US5436011A (en) * 1993-04-16 1995-07-25 Bristol-Myers Squibb Company Solid pharmaceutical dosage form and a method for reducing abrasion
WO1995001166A1 (en) * 1993-06-30 1995-01-12 Fujisawa Pharmaceutical Co., Ltd. Encapsulated medicine
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
AU695734B2 (en) 1996-07-08 1998-08-20 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
SE9704401D0 (sv) * 1997-11-28 1997-11-28 Astra Ab Matrix pellets for greasy, oily or sticky drug substances
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US7919109B2 (en) * 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
CN1232244C (zh) * 1999-02-08 2005-12-21 阿尔萨公司 稳定的非水性单相粘性载体及采用该载体的制剂
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
CA2388471A1 (en) * 1999-09-27 2001-04-05 Richard William Saunders Pharmaceutical carrier formulation
US6831079B1 (en) * 1999-09-27 2004-12-14 American Cyanamid Company Vasopressin agonist formulation and process
CA2352211C (en) 1999-09-30 2009-03-24 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP2007070344A (ja) * 2005-08-11 2007-03-22 Tsukioka:Kk 内服薬
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
KR101575679B1 (ko) * 2006-08-30 2015-12-08 자고텍 아게 코어 및 하나 이상의 배리어 층을 포함하는 방출 제어형 경구 투여 제제
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
CN107638562B (zh) 2009-09-28 2022-12-02 精达制药公司 基本稳态药物递送的快速建立和/或终止
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU432703A3 (es) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
JPS5035324A (es) * 1973-08-01 1975-04-04
JPS542316A (en) * 1977-06-07 1979-01-09 Yamanouchi Pharmaceut Co Ltd Solid pharmaceutical composition containing nifedipene
JPS5734854A (en) * 1980-08-08 1982-02-25 Nippon Chemiphar Co Novel slowly diffusing powdered and granular body, elution of medicine therefrom is adjusted, and its manufacture
DE3124983A1 (de) * 1981-06-25 1983-01-20 Meditest Inst Fuer Medizinisch Arzneiformen zur oralen verabreichung
JPS58109412A (ja) * 1981-12-23 1983-06-29 Toa Eiyou Kagaku Kogyo Kk ニフエジピン固形製剤
JPS591417A (ja) * 1982-06-28 1984-01-06 Toyo Jozo Co Ltd 持続性セフアレキシン錠およびその製造法
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
DE3437917A1 (de) * 1984-10-17 1986-04-17 Bayer Ag, 5090 Leverkusen Kombination von dihydropyridinen mit ace-hemmern sowie ihre verwendung in arzneimitteln
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition

Also Published As

Publication number Publication date
EP0265848B1 (de) 1991-09-25
ATE67677T1 (de) 1991-10-15
DE3636123C2 (es) 1989-06-01
JPH0737384B2 (ja) 1995-04-26
EP0265848A1 (de) 1988-05-04
JPS63104921A (ja) 1988-05-10
DE3636123A1 (de) 1988-05-05
US5071642A (en) 1991-12-10
DE3773327D1 (de) 1991-10-31

Similar Documents

Publication Publication Date Title
ES2040232T3 (es) Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
FI920956A0 (fi) Doseringsform foer administrering av oral hypoglykemisk glipisid.
DE3382641D1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
GR80327B (en) Means for transdermic application of active drug substances
DE69331409T2 (de) Oral 1alpha-hydroxyprevitamin d
NO306377B1 (no) Doseform for avgivelse av et medikament
IT7849462A0 (it) Corpo di capsula in particolare per una capsula per la somministrazione di sostanze medicamentose come pure procedimento e dispositivo per lasua produzione
EP0151989A3 (en) Means for the treatment of cardiac diseases
ES2034035T3 (es) Procedimiento de preparacion de una forma farmaceutica para la administracion y/o dosificacion de medicamentos.
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
KR910005858A (ko) 지방산 요법
IT8219482A0 (it) Composizione farmaceutica per la cura di affezioni della cavita'orale.
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
NO810480L (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive 1,3,4-oksadiazolylfenol-derivater
ATE5073T1 (de) 5-amino-tetrazol-derivate von retinsaeuren, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
MY101916A (en) Etoposide oral dosage form.
GR3018365T3 (en) Use of 15-deoxyspergualine as a medicament.
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
SE9101341D0 (sv) New medicinal use
KR880002521A (ko) 약제 제형
AR002946A1 (es) Un conjunto para uso en el tratamiento o la prevencion de la osteoporosis en los mamiferos de acuerdo con una dieta ciclica.
JPS57139013A (en) Prophylactic or remedy for periodontosis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 265848

Country of ref document: ES